Jeffrey Allen 2.7 3 ideas

Jeffrey Allen notes that "Beast Games season one attracted 50 million viewers in its first 25 days, streaming on Amazon Prime." This viewership metric confirms the success of Amazon's strategy to integrate top-tier "Creator Economy" talent (MrBeast) into Prime Video. High engagement drives Prime retention and high-value video ad inventory, differentiating Amazon from legacy studios. Long Amazon as it successfully bridges YouTube-style content with premium streaming infrastructure. High production costs for exclusive content; saturation of the streaming market.

Jeffrey mentions that for his son's disease (CTD), pharmaceutical companies are looking at "ASO therapy" (Antisense Oligonucleotide) and "prodrugs" to bypass the blood-brain barrier. Ionis (IONS) is the market leader in RNA-targeted ASO therapies, and Ultragenyx (RARE) specializes in rare genetic diseases and metabolic disorders. When a specific modality like ASO is highlighted as the solution for neurological transport issues, it validates the broader technology platforms of these specialized firms. Watch these tickers as proxies for advancements in ASO and rare disease drug delivery. Clinical trial failures are common in rare disease; "science is slow" (as stated by the guest).